Sugammadex-Associated Hypotension, Bradycardia, Asystole, and Death

Mirza, Kazim and Landoski, Kathryn and Thakar, Dilip and Heir-Singh, Jagtar and Jackson, Timothy and Kassab, Cynthia (2020) Sugammadex-Associated Hypotension, Bradycardia, Asystole, and Death. Case Reports in Anesthesiology, 2020. pp. 1-2. ISSN 2090-6382

[thumbnail of 8767195.pdf] Text
8767195.pdf - Published Version

Download (1MB)

Abstract

On December 16, 2015, the Food and Drug Administration (FDA) in the United States approved sugammadex (Bridion, Merck and Co), a modified gamma-cyclodextrin, to be used as a reversal agent. It is a first and unique selective nondepolarizing steroidal muscle relaxant (NDSMR) binding agent with a great affinity for rocuronium and vecuronium. However, there have been several recently published case reports of bradycardia and asystole immediately after sugammadex administration for the reversal. This report presents a case of sugammadex administration followed by rapidly progressing bradycardia leading to asystole and subsequent death. The family has provided the written consent to share this case report.

Item Type: Article
Subjects: Journal Eprints > Medical Science
Depositing User: Managing Editor
Date Deposited: 25 Nov 2022 04:59
Last Modified: 25 May 2024 07:44
URI: http://repository.journal4submission.com/id/eprint/342

Actions (login required)

View Item
View Item